The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nogai, A.
Right arrow Articles by Kamradt, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nogai, A.
Right arrow Articles by Kamradt, T.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CYCLOSPORIN A
The Journal of Immunology, 2005, 175: 959-966.
Copyright © 2005 by The American Association of Immunologists

Lipopolysaccharide Injection Induces Relapses of Experimental Autoimmune Encephalomyelitis in Nontransgenic Mice via Bystander Activation of Autoreactive CD4+ Cells1

Axel Nogai2,*, Volker Siffrin2,*, Kerstin Bonhagen2,*,{dagger}, Caspar F. Pfueller*, Thordis Hohnstein*, Rudolf Volkmer-Engert{ddagger}, Wolfgang Brück§, Christine Stadelmann§ and Thomas Kamradt3,*,{dagger}

* Deutsches Rheumaforschungszentrum Berlin, Berlin, Germany; {dagger} Institut für Immunologie, Klinikum der Friedrich-Schiller-Universität Jena, Jena, Germany; {ddagger} Institut für Medizinische Immunologie, Universitätsklinikum Charité, Berlin, Germany; and § Institut für Neuropathologie, Universität Göttingen, Göttingen, Germany


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Infections sometimes associate with exacerbations of autoimmune diseases through pathways that are poorly understood. Ag-specific mechanisms such as cross-reactivity between a microbial Ag and a self-Ag have received no direct support. In this study, we show that injection of LPS induces experimental autoimmune encephalomyelitis in TCR-transgenic mice and relapse of encephalomyelitis in normal mice. This form of treatment induces proliferation and cytokine production in a fraction of effector/memory Th lymphocytes in vitro via physical contact of Th cells with CD4– LPS-responsive cells. TCR-mediated signals are not necessary; rather what is required is ligation of costimulatory receptors on Th cells by costimulatory molecules on the CD4– cells. This form of bystander activation provides an Ag-independent link between infection and autoimmunity that might fit the clinical and epidemiological data on the connection between infection and autoimmunity better than the Ag-specific models.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Multiple sclerosis (MS)4 is a chronic inflammatory demyelinating disease of the CNS. Its natural history in most patients is characterized by a course of exacerbations and remissions. Its etiology is unknown, involving both genetic and environmental factors. Current evidence strongly suggests that MS is an immune-mediated disease (1, 2, 3). The murine model of MS, experimental autoimmune encephalomyelitis (EAE), can be induced by activation or adoptive transfer of T cells that recognize myelin Ags (4). Activation of autoreactive T cells is, therefore, believed to be important for the induction, maintenance, and regulation of the inflammatory demyelination in EAE and MS (5, 6).

Epidemiological, clinical, and experimental evidence identifies autoimmunity as a potential sequel of infection (7). Exacerbation of MS is two to three times more likely to occur during or shortly after common respiratory, gastrointestinal, or urological infections (8, 9, 10, 11). Much of the search for immunological pathways connecting infection to autoimmunity has been focused on Ag-specific immune responses. A particularly plausible hypothesis is that sequence similarity between microbial and self-Ags (molecular mimicry) activates autoreactive lymphocytes (12, 13). Supporting this hypothesis are reports of T cells that recognize both microbial and myelin peptides (14, 15, 16, 17) and of EAE induced by immunization with microbial peptides (16, 17, 18). However, epidemiological studies have failed to link induction or exacerbations of MS with any particular infection (8, 9, 10, 11, 19, 20), and T cell recognition of Ag is quite degenerate, so that an individual TCR can often recognize both microbial and self-peptides (21). Evidently, cross-reactivity between a particular microbial Ag and a particular self-Ag is unlikely, in general, to induce autoimmune disease. Additional mechanisms are needed to induce pathogenic autoimmune responses (13, 22).

For full activation, T cells require costimulatory signals from APC in addition to Ag recognition. The expression of many costimulatory molecules on APC is up-regulated in response to infection (23, 24). This is one aspect of the crucial role of the innate immune system in initiating and directing adaptive immune responses, both protective and pathological (25, 26). In this study, we show that injection of LPS, a potent activator of the innate immune system, induces TCR-independent bystander activation of autoreactive CD4+ Th cells which induce EAE in TCR-transgenic mice and relapse of the disease in normal mice.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Antigens

Peptides MBPAc1–11 (AcASQKRPSQRSK) and MBP85–99 (ENPVVHFFKNIVTPR) were synthesized as described previously (17). Lysed Salmonella typhimurium strain C5 Nalr were from U. E. Schaible (Max-Planck-Insitut für Infektionsbiologie, Berlin, Germany). S. typhimurium LPS (ATCC source strain 7823, purified by gel filtration) and OVA were obtained from Sigma-Aldrich. Some experiments were also repeated with ultrapure LPS from Salmonella abortus equi (ALX-581-009; Alexis), which is free from potentially TLR2-stimulating contaminations.

Mice

Mice transgenic for a TCR that recognizes MBPAc1–11/I-Au (27) were crossed onto TCR {alpha}-chain-deficient mice, resulting in mice expressing only the transgenic TCR (T+{alpha}– mice), which were provided by J. Lafaille (Skirball Institute, New York, NY). Mice transgenic for the same myelin basic protein (MBP)-specific TCR and deficient for RAG-1 (T+R– mice) were from J. Demengeot (Instituto Gulbenkian de Ciência, Oeiras, Portugal). TCR expression was checked as described previously (17). Other mice were purchased from The Jackson Laboratory. Mice were kept in specific pathogen-free conditions. All animal experiments were approved by the appropriate state committees for animal welfare.

EAE induction

Ag in CFA was injected s.c. Ag was 200 µg peptide, 108 lysed S. typhimurium, or 50 µg LPS. Pertussis toxin (PT, 200 ng; Sigma-Aldrich) was injected i.v. at days 0 and 2 after immunization. EAE was scored as follows: 0, healthy; 1, limp tail; 2, partial hind leg paralysis; 3, complete hind leg paralysis; 4, tetraparesis; and 5, moribund. Mice were sacrificed when their score reached 4- 5 and their score was kept at 5 for the remainder of the experiment.

Histological analysis

Histological analysis was performed as described elsewhere (28). Sections were stained with H&E, Luxol Fast Blue, and Bielschowsky silver impregnation to assess inflammation, demyelination, and axonal loss, respectively. In adjacent serial sections, immunohistochemistry was performed with Abs against macrophages/activated microglia (Mac-3, clone M3/84; BD Pharmingen), T cells (CD3-12; Serotec), B cells (B220, clone RA3-6B2; BD Pharmingen), and early invading macrophages (S100A9, kindly provided by C. Sorg, Münster, Germany) (29). The S100A9 Ab also recognizes polymorphonuclear granulocytes. Bound Ab was visualized using an avidin-biotin technique with diaminobenzidine as chromogen. Control sections were incubated in the absence of primary Ab and with isotype control Abs.

In vitro assays

Single-cell suspensions were prepared from spleens in RPMI 1640 (PAA) supplemented with 10% FCS, 2 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 50 µM 2-ME (complete medium, CM) as described (17). Spleen cells (SC) were cultured at 37°C in 5% CO2 with peptides, LPS, staphylococcal enterotoxin B (SEB, 2 µg/ml; Sigma-Aldrich), plate-bound anti-CD3 mAb (145-2C11, 3 µg/ml), and anti-CD28 mAb (37.51, 2.5 µg/ml) or in CM alone. For Transwell experiments, CD4+ and CD4– cells were purified by MACS (Miltenyi Biotec). Purity of the separated fractions was >97% in all experiments. Transwells (0.4-µm pores; Costar) were used to separate the two populations. CD4+ cells were in the upper chamber. The lower chamber contained CD4– APC. Cells were cultured with MBP, LPS, or CM alone for 24 h before cytokine production was analyzed flow cytometrically. SC were incubated for 1 h in CM with DMSO (0.1%) or with 50 nM cyclosporin A (CsA; Arzneimittelwerk Dresden) in DMSO before MBP or LPS was added for 24 h. For blocking experiments, SC were cultured for 24 h in the presence of LPS with or without the addition of 20 µg/ml anti-CD18 (M18/2.a.12.7), anti-CD54 (BE29G1), anti-CD80 (16-10A1), anti-CD86 (GL1), anti-ICOS-L (MIL-4495, kindly provided by R. Kroczek, Berlin, Germany), or CTLA-4-Ig 1 h before cytokine production was determined flow cytometrically.

Flow cytometry

Cells were stained with allophycocyanin, Cy5, or FITC-conjugated mAbs against CD4 (GK1.5), CD25 (2E4; BD Pharmingen), and biotinylated CD69 (H1.2F3; BD Pharmingen). Biotinylated primary mAbs were detected with streptavidin coupled to PE (BD Pharmingen). Samples were incubated with blocking anti-Fc{gamma}RII/III mAb 2.4G2/75 and purified rat IgG. For analysis of proliferation, SC were incubated with CFDA-SE (Molecular Probes) at 5 µg/ml for 5 min, cultured with CM alone or Ags for 3 days, stained with Cy5-labeled anti-CD4, PE-labeled anti-B220, and analyzed by flow cytometry. For analysis of cytokine production, SC were cultured for 18 h in vitro before 5 µg/ml brefeldin A (Sigma-Aldrich) was added for the last 6 h of culture. Samples were analyzed on a FACSCalibur and analysis was performed with CellQuest software (BD Biosciences) or FCS express (De Novo software) as described previously (30).

Statistical methods

Statistical significance was determined by a two-sided Fisher exact test.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Immunization with S. typhimurium or LPS induces EAE in T+{alpha}– mice

We had shown earlier that a TCR that recognizes MBPAc1–11/I-Au also recognizes a large number of microbial peptides. One of these peptides was derived from S. typhimurium and immunization with this peptide induced EAE in mice whose T cells exclusively express that receptor (T+{alpha}– mice) (17). Immunization of T+{alpha}– mice with lysed S. typhimurium/CFA followed by PT induced EAE with the same incidence, similar kinetics, and severity as immunization with the MBPAc1–11 peptide (Fig. 1 and Table I). However, presentation and recognition of the cross-reactive peptide was not necessary. Immunization with LPS from S. typhimurium also induced EAE in the T+{alpha}– mice (Fig. 1 and Table I). Different from another transgenic model (31), the T+{alpha}– mice did not develop EAE when immunized with PBS/CFA followed by PT (Fig. 1 and Table I). LPS-induced EAE was T cell dependent because LPS immunization did not induce EAE in littermates of the T+{alpha}– mice that do not express the MBPAc1–11-specific transgenic TCR ({alpha}– mice) (Table I).



View larger version (33K):
[in this window]
[in a new window]
  		FIGURE 1. Immunization with LPS induces EAE in T+{alpha}– mice. T+{alpha}– mice were immunized with MBPAc1–11, LPS, S. typhimurium lysate, or PBS, followed by PT. Data represent mean EAE scores (±SEM). Data shown are pooled from three independent experiments, each containing at least five mice per group. Animals were sacrificed when their score reached 4 or higher, and their score was kept at 5 for the remainder of the experiment.

 

View this table:
[in this window]
[in a new window]
  		Table I. EAE incidence in different strains of mice

 
No difference in the extent of inflammation and demyelination was detectable on H&E- and Luxol Fast Blue-stained sections between MBPAc1–11- or LPS-induced EAE. Furthermore, immunohistochemistry for T cells, B cells, and macrophages revealed no discernible differences in the composition of the inflammatory infiltrates (Fig. 2).



View larger version (69K):
[in this window]
[in a new window]
  		FIGURE 2. Similar histopathology of EAE induced by MBPAc1–11 or LPS. T+{alpha}– mice were immunized with MBPAc1–11 (upper panels) or LPS (lower panels) followed by PT. Mice that had reached a clinical stage 3 were sacrificed and prepared for histological analysis. Prominent perivenous and subpial inflammation is present in both groups (H&E staining, a and e). Immunohistochemistry for Mac-3 (b and f), CD3 (c and g), or B220 (d and h) shows no significant difference in cellular composition of the inflammatory infiltrate between the two groups of mice. Data shown are representative for at least three mice per treatment group. Scale bar, 50 µm.

 
LPS immunization induces EAE relapses in SJL mice

Only the T+{alpha}– mice that harbor a quasi-monoclonal T cell repertoire developed EAE upon LPS immunization. Naive nontransgenic SJL, PL/J, or B10.PL mice were resistant (Table I). To determine whether previous activation and expansion of MBP-specific Th cells made genetically unaltered SJL mice susceptible to LPS-induced EAE, we immunized SJL mice with MBP85–99. This induced monophasic EAE in 65% of the SJL mice ~2 wk after the immunization. Almost all of the mice had recovered 40 days after the immunization (Table II). On day 45, we injected the mice with LPS or PBS followed by PT. Only 2 of the 20 PBS-injected mice suffered a relapse of EAE (Table II) and the clinicalsymptoms were mild (score 2). In contrast, immunization with LPS induced a relapse in 13 of 28 mice (p < 0.02, Table II). Similar results were obtained when we injected the mice with ultrapure LPS (data not shown), demonstrating that the LPS effect was not due to contaminating TLR2 ligands. The mean clinical score (2.5) was higher than during the first episode of EAE and some of the mice had severe symptoms (score 4). Ten of 17 mice that had developed EAE upon MBP immunization on day 0 developed an EAE relapse following the LPS immunization on day 45. Similarly, 5 of 11 mice of the mice that had not developed EAE upon MBP immunization on day 0 developed EAE following the LPS immunization (p = 0.7). Therefore, a previous EAE episode is not necessary to make SJL mice susceptible to LPS-induced EAE, rather the T cell activation induced by MBP immunization is both necessary and sufficient. In contrast to the MBP-immunized mice, none of the SJL mice that were immunized with OVA on day 0 and with LPS on day 45 developed EAE (Table II). Together, these results indicate that MBP-specific effector/memory T cells, but not naive T cells or effector/memory T cells that recognize irrelevant, non-CNS Ags such as OVA, mediate bystander-induced EAE.


View this table:
[in this window]
[in a new window]
  		Table II. Induction of EAE relapse in nontransgenic SJL mice

 
MBP85–99-immunized SJL mice had perivascular and subpial inflammatory infiltrates of T cells, macrophages, B cells, and granulocytes (Fig. 3, a–e). Mice injected with PBS at day 40 and without clinical relapse showed subpial scars at day 75, but no evidence of recent inflammation (Fig. 3, f–k), whereas mice immunized with LPS and with clinical signs of relapsing disease had extensive, highly cellular subpial lesions with polymorphonuclear granulocytes and macrophages expressing the early macrophage marker S100A9 as evidence of recent invasion of inflammatory cells into the lesion (Fig. 3, l–p).



View larger version (103K):
[in this window]
[in a new window]
  		FIGURE 3. LPS-induced EAE relapses in SJL/mice. Histological analysis reveals perivascular and subpial infiltrates (H&E staining, a) comprised of Mac-3-positive macrophages (b), CD3-positive T cells (c), few B220-positive B cells (arrows, d), and some S100A-positive polymorphonuclear granulocytes and early invading macrophages (e) in SJL mice immunized with MBP85–99 suffering from the first bout of disease (day 20 after immunization). In animals immunized with PBS/CFA on day 40 after the first immunization, subpial scars (f) with foamy macrophages (g), perivascular T cell cuffing (arrows, h), few B cells (arrows, i) and almost no S100-positive granulocytes and macrophages (arrow, k) are recognized (day 75 after immunization). Mice immunized with LPS/CFA on day 40 after the first immunization show extensive, highly cellular subpial inflammation (l, H&E; m, anti-Mac-3, macrophages; n, anti-CD3, T cells; o, anti-B220, B cells) with abundant S100A9-positive cells (p), indicating recent recruitment of inflammatory cells into the lesion (day 75 after immunization). Representative spinal cord cross-sections were chosen for photography. All animals depicted had equal clinical EAE scores (level 2) at their first bouts, permitting a direct comparison of lesional pathology. Scale bar, 50 µm.

 
LPS induces bystander activation of Th cells in vitro

LPS is not known to have direct effects on murine Th cells but potently induces the expression of cytokines and costimulatory molecules in cells of the innate immune system. To investigate the immunological mechanisms leading to LPS-induced EAE, we examined whether LPS-induced activation of the innate immune cells caused Th cell activation in vitro. Therefore, we cultured SC from T+{alpha}– mice in CM alone or with MBPAc1–11 or LPS. LPS induced proliferation of 1.0–1.5% of the CD4+ T cells (Fig. 4a). This was significantly above background proliferation (CM alone: 0.2–0.4%, p < 0.015 in five independent experiments). LPS-induced T cell proliferation depended on the presence of CD4– cells and was not detectable when CD4– cells were depleted from the cultures (our unpublished data). LPS also induced up-regulation of both CD69 and CD25 in T+{alpha}– mice: >20% of the CD4+ T cells were CD69+ and ~2% expressed CD25 after a 24-h culture in the presence of LPS (Fig. 4b). Similar results were obtained when we used ultrapure LPS, which does not contain TLR2-stimulating contaminants (Fig. 4b).



View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 4. LPS-induced bystander activation of CD4+ cells. a, CFSE-labeled SC from T+{alpha}– mice were cultured in CM alone in the presence of MBPAc1–11 or LPS. Seventy-two hours later, the cells were stained with Abs against CD3 and CD4 and analyzed flow cytometrically. Gates were set on the CD3+ population. Numbers in the upper left quadrants indicate the percentage of CD4+ cells that had divided at least once. b, SC from T+R– mice were cultivated for 1 day either in CM alone, in the presence of MBPAc1–11, LPS, or ultrapure LPS (LPSup), and stained for CD3, CD4, CD25, and CD69. Gates are set on CD3+CD4+ cells. c, SC from SJL mice that were either unimmunized (upper panels) or had been immunized 45 days earlier with MBP85–99 (lower panels) were cultured for 24 h in CM alone or in the presence of SEB, MBPAcl–II, or LPS and stained for CD3, CD4, and intracellular cytokines. Gates are set on CD3+CD4+ cells. d, SJL mice were immunized with MBP85–99/CFA followed by PT ({blacksquare}, +PT) or PBS i.v. ({square}, – PT). Forty-five days later, SC were cultured for 3 days in CM alone or with MBP85–99, LPS, or ultrapure LPS (LPSup) added to the culture. The expression of the activation marker CD69 was determined flow cytometrically. Data are characteristic of three independently performed experiments.

 
Effector/memory cells from previously immunized mice were more susceptible to LPS-induced bystander activation than Th cells from unimmunized mice. When SC from normal SJL mice that had been immunized with MBP85–99 45 days earlier (henceforth MBP85–99-immunized mice) were cultured with LPS, ~1.5% of them produced IFN-{gamma} or TNF-{alpha} (Fig. 4c). The percentages of cytokine-producing Th cells were similar when SC from SJL mice that had been preimmunized with OVA were cultured with LPS in vitro (our unpublished observations). In contrast, <0.5% of the CD3+CD4+ cells from naive healthy SJL mice produced IFN-{gamma} or TNF-{alpha} in response to LPS (Fig. 4c). SJL mice that had been immunized with MBP/CFA s.c. followed by PT i.v. responded similarly to SJL mice that had been immunized with MBP/CFA s.c. followed by PBS i.v. Thus, previous in vivo exposure to PT was not necessary for susceptibility to LPS-induced bystander activation (Fig. 4d).

Taken together, effector/memory Th cells of different Ag specificities are susceptible to LPS-induced bystander activation. However, only autoreactive effector/memory Th cells cause disease upon LPS-induced bystander activation (Table II).

LPS does not act directly on CD4+ T cells

Unsorted SC produced IFN-{gamma} and TNF-{alpha} in response to LPS but not in CM alone (Fig. 5a). We purified CD4+ cells from MBP85–99-immunized SJL mice by MACS (purity >98%). When the purified CD4+ cells were cultured along with CD4– cells and LPS, the fraction of cytokine-producing CD4+ cells was the same as in total SC (Fig. 5a). In contrast, purified CD4+ cells alone did not respond to LPS (Fig. 5a). Thus, LPS has no direct effect on Th cells. Instead, LPS-induced bystander activation of Th cells depends on the activation of CD4– cells by LPS.



View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 5. LPS-induced bystander activation of Th cells depends on physical contact between CD4+ cells and APC. a, SC (light gray bars) or MACS-purified CD4+ cells from the spleens of MBP85–99-immunized SJL mice were cultured in CM (medium) or in CM + LPS (LPS). MACS-purified CD4+ cells from the spleens of MBP85–99-immunized SJL mice plus purified CD4– cells were cultured together (open bars) or CD4+ cells were placed in the upper chamber of Transwell plates and CD4– cells were in the lower chamber (black bars). Isolated CD4+ cells (dark gray bars) are shown as control. Cytokine production was analyzed flow cytometrically. The percentage of IFN-{gamma}- and/or TNF-{alpha}-producing CD4+ cells ± SEM from three independent experiments is indicated. b, SC from MBP85–99-immunized SJL mice were preincubated for 1 h with 50 nM CsA in DMSO or in DMSO (0.1%) alone and then cultured in CM alone, MBP, or LPS for 24 h. Production of IFN-{gamma} and TNF-{alpha} in CD4+ cells was analyzed by flow cytometry. Numbers in the quadrants indicate the percentage of cytokine-producing CD4+ cells. c, SJL mice were immunized with MBP85–99 s.c. in CFA followed by PT immediately and 48 h after the immunization. Forty days later, SC were sorted into CD4+ Th cells and CD4–CD8– APC. On the same day, SC from unimmunized SJL mice were also sorted into CD4+ Th cells and CD4–CD8– APC. Th from either naive (Thn) or immunized (Thi) animals were then mixed at a 1:2 ratio with APC from either naive (APCn) or immunized (APCi) animals and cultured with medium alone, MBP85–99, or LPS. The production of IFN-{gamma} was determined flow cytometrically. The results are characteristic of at least three independent experiments.

 
LPS-induced bystander activation depends on cell-cell contact and is not mediated by soluble factors

LPS-induced bystander activation of Th cells could be mediated either by soluble factors produced by the LPS-responsive CD4– cells or by cell-cell contact between the LPS-responsive cells and the Th cells. To distinguish between these possibilities, we placed MACS-purified CD4+ cells from MBP85–99-immunized SJL mice in the upper chamber of a Transwell system. The lower chamber contained CM alone, CM and LPS, or LPS and CD4– cells. When CD4+ cells were cultured in the upper chamber and APC in the lower chamber, the CD4+ cells no longer produced IFN-{gamma} or TNF-{alpha} in response to LPS (Fig. 5a). The sorted CD4+ cells in the upper chamber were viable as demonstrated by the fact that they produced both IFN-{gamma} and TNF-{alpha} upon stimulation with anti-CD3/anti-CD28 (our unpublished data). Supernatants from LPS-stimulated SC did not induce IFN-{gamma}- or TNF-{alpha} production in the CD4+ cells (our unpublished data). Furthermore, addition of the selective p38 MAPK inhibitor SB203580, which inhibits IL-12- and IL-18-induced IFN-{gamma} production of murine Th1 cells (32), had no effect on LPS-induced cytokine production in the CD4+ effector/memory cells (our unpublished data). Taken together, LPS-induced bystander activation of CD4+ cells depends on physical contact of Th cells with LPS-responsive APC.

CsA does not inhibit bystander activation

Since LPS-induced bystander activation of CD4+ cells is contact dependent, we asked whether TCR-mediated signaling was necessary. CsA inhibits TCR-induced expression of IFN-{gamma} (32). We cultured SC from naive or MBP85–99-immunized SJL mice with SEB, MBP85–99, or LPS in the presence or absence of CsA and determined the cytokine production of CD4+ cells. CsA inhibited the IFN-{gamma} production in response to either SEB or MBP85–99 almost completely (Fig. 5b). In contrast, CsA did not inhibit the IFN-{gamma} or TNF-{alpha} production of naive Th cells in response to LPS (data not shown) and only marginally inhibited the LPS-induced IFN-{gamma} production of effector/memory Th cells (Fig. 5b). Thus, LPS-induced bystander activation of Th cells proceeds via signaling pathways distinct from the TCR-mediated triggering of calcineurin. The APC used in these experiments could have still been loaded with Ag. To test this possibility, we performed experiments in which APC (CD4–CD8– SC) from either naive or immunized animals were cultured with T cells from either naive or immunized animals. When Th cells from unimmunized animals (Thn) were cultured along with APC from either unimmunized (APCn) or immunized (APCi) animals, there was no detectable IFN-{gamma} production in response to either medium or MBP85–99 and little IFN-{gamma} production in response to LPS (Fig. 5c, left panels). Only Th cells from immunized animals (Thi) produced IFN-{gamma} in response to MBP85–99 and that response was stronger when both the Th and the APC came from immunized mice (Fig. 5c, right panels). Supporting the data shown in Fig. 4c, Th cells from immunized animals produced more IFN-{gamma} in response to LPS than Th cells from unimmunized animals (Thn) did. Interestingly, the response was slightly stronger when both the Th and the APC were from previously immunized mice. Yet, the pertinent point is that a significant percentage of Th cells from immunized animals produced IFN-{gamma} when cultured with APC from unimmunized animals and LPS.

Costimulatory molecules of the B-7 family are necessary for LPS-induced bystander activation

We next asked whether the costimulatory molecules were essential for LPS-induced bystander activation. SC from MBP85–99-immunized SJL mice were cultured in CM alone or with LPS in the presence or absence of different mAbs or combinations thereof. Blockade of the ICAM-1:LFA-1 interaction with anti-CD54 reduced the LPS-induced IFN-{gamma}-production by ~25% (Fig. 6b). Neither anti-CD80 nor anti-CD86, anti-ICOSL, or CTLA4-Ig alone influenced the LPS-induced cytokine production strongly (Fig. 6), but the combination of these reagents reduced the number of cytokine-producing CD4+ cells by ~50% (anti-B7 family, Fig. 6). Addition of anti-CD54 to that combination only marginally reduced the IFN-{gamma}- production further. Taken together, LPS-induced bystander activation of Th cells is at least partly mediated by the contact between costimulatory ligands of the B7 family on APC, some of which are up-regulated in response to LPS, and their receptors on CD4+ Th cells.



View larger version (32K):
[in this window]
[in a new window]
  		FIGURE 6. LPS-induced bystander activation depends on interactions between B7-family members and their receptors on Th cells. SC from MBP85–99-immunized SJL mice were cultured for 24 h in the presence of LPS with or without the addition of Abs against the indicated surface molecules or with CTLA-4-Ig. Each mAb was used in a concentration of 20 µg/ml. Anti-B7 family indicates the combination of anti-CD80, anti-CD86, anti-ICOSL, and CTLA4-Ig. IFN-{gamma} production in CD4+ cells was analyzed by flow cytometry. a, Cytokine production of CD4+ cells cultured in LPS alone or after preincubation with the indicated mAbs. b, The cytokine production of CD4+ cells after culture with LPS alone from six individual mice was set as 1 and the other values are given as fraction of that value ± SEM.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
In this report, we show that LPS injection induces EAE relapses in genetically unaltered mice and bystander activation of Th cells. Previous reports had either demonstrated adjuvant effects of TLR ligands, such as LPS in vitro (33, 34, 35, 36, 37), or the induction of autoimmune disease through systemic injection of PT or CpG in transgenic mice (31, 38). Addition of LPS to the in vitro culture enhances the encephalitogenic potential of MBP-specific T cells upon adoptive transfer into syngeneic recipients (33, 35). In otherwise EAE-resistant B10.S mice, EAE can be induced passively if CpG or LPS plus IFN-{gamma} are added to the in vitro culture before adoptive transfer (34). Moreover, if lymph node cells from mice or rats that had been tolerized toward myelin Ags are cultured in the presence of CpG in vitro, they become encephalitogenic upon adoptive transfer into syngeneic recipients (36, 37). Taken together, myelin-specific cells that are unable to adoptively transfer EAE if cultured with myelin Ags alone can be rendered encephalitogenic through in vitro culture with myelin Ags in the presence of CpG or LPS. Reports on the active induction of EAE by injection of Ag-nonspecific stimuli in vivo have thus far been restricted to transgenic mouse models. EAE can be induced by injection of PT alone in some, but not all, strains of mice transgenic for a MBP-specific TCR (31), and CpG injection induces EAE in a fraction of B10.S mice that express a proteolipid protein-specific TCR (38). Our finding that LPS injection induces EAE in T+{alpha}– mice (Fig. 1) confirms and extends these reports. The important novel finding presented in this report is the active induction of EAE relapses in normal mice upon LPS injection without the need for adoptive transfer of in vitro-cultured myelin-specific cells.

Immunization with PBS/CFA followed by PT i.v. did not induce EAE in T+{alpha}– mice or EAE relapses in SJL mice. Thus, LPS is necessary in both models and EAE is not due to the injection of PT, which has several known EAE-promoting effects, such as increasing Th1 responses and enhancing the T cells’ access to the CNS (39, 40, 41)

A novel mechanism for Ag-independent T cell activation

Bystander activation has been used to describe different phenomena. We use this term to indicate T cell activation that occurs independently of Ag recognition by the TCR. In accordance with earlier studies (42, 43, 44, 45, 46), we found that memory/effector T cells were more susceptible to TCR-independent bystander activation than naive Th cells. However, LPS-induced bystander activation of CD4+ cells described here differs from the cytokine-driven bystander activation depicted in the earlier studies (32, 42, 43, 44, 45, 46, 47, 48, 49) in several important aspects. Most important, soluble factors such as cytokines do not mediate LPS-induced bystander activation. This is also different from the in vitro adjuvanticity of the TLR ligands LPS or CpG, which were observed in adoptive transfer models of EAE. Those effects could be mimicked by addition of IL-12 to the culture (34, 36, 37). In contrast to a recent study that reported the detection of TLR4 mRNA in MACS-purified CD4+CD25+ T cells (50), we did not find any direct LPS effects on highly purified CD4+ T cells.

Instead, physical contact between LPS-responsive CD4– cells and CD4+ Th cells is necessary for LPS-induced bystander activation of Th cells. The interaction between costimulatory molecules of the B7 family on LPS-activated CD4– cells and their receptors on Th cells is an important but not the only mechanism for LPS-induced bystander activation of Th cells. Blockade of the costimulatory ICAM-1:LFA-1 interaction (51) also reduced the LPS-induced cytokine production significantly (see Fig. 6). Furthermore, enhanced costimulation via members of the TNFR family (24) may well play a role in LPS-induced bystander activation of Th cells. Taken together, our data show that under certain circumstances costimulatory signals provided by activated APC can induce T cell activation in the absence of TCR triggering. Similar observations have been made with "superagonistic" Abs against CD28 in rats (52, 53) and with pairs of Abs against human CD2 (54). The question remains, which regulatory processes usually prevent T cell activation by costimulatory signals alone and under which circumstances in vivo costimulatory signals alone suffice to cause T cell activation. It is conceivable that bystander activation in vivo may have beneficial effects. For example, bystander activation might contribute to the maintenance of T cell memory similar to what has been described for B lymphocytes (55).

Induction of autoimmunity by Ag-independent T cell activation

Bystander activation of autoreactive Th cells occurs independently of TCR Ag recognition and fits the clinical and epidemiological data on the connection between infection and autoimmunity. A variety of infections increase the risk for exacerbations in MS patients (8, 9, 10, 11), but despite extensive efforts no specific pathogen has been identified as culprit (2, 3, 7, 19). Bystander activation of autoreactive Th cells occurs independently of TCR Ag recognition and fits the clinical and epidemiological data on the connection between infection and autoimmunity better than supposed Ag-specific mechanisms. The following scenario could link infection and autoimmunity via bystander activation: autoreactive T cells are part of the normal repertoire (56, 57, 58). The frequency of these autoreactive Th cells is one of the genetically determined factors that contribute to susceptibility to autoimmune diseases (59). Survival and expansion of autoreactive Th cells can be supported either by recognition of self-Ag and overt autoimmune attacks or, clinically silent, by the recognition of cross-reactive microbial peptides (18, 21). Once the number of autoreactive T cells has reached a certain threshold, as in the monoclonal T+{alpha}– mice or following MBP immunization in the nontransgenic mice, or in patients who have already suffered previous episodes of MS, TCR-independent stimuli such as LPS-induced bystander activation can trigger sufficient numbers of autoreactive T cells to cause autoimmune damage. This scenario is different both from the Ag-dependent adjuvant effects of LPS (60, 61, 62, 63) and from bystander damage which can occur in virally infected mice with a monoclonal T cell repertoire (64, 65, 66). Both the Ag-specific activation of the monoclonal T cells and the simultaneous viral infection at the site of tissue damage are necessary conditions for the induction of bystander damage which can result in diabetes (64), keratitis (65), or encephalitis (66). In sharp contrast, TCR-mediated signals are not required for the LPS-induced bystander activation of Th cells described here.

Only 50% of the LPS-immunized SJL mice had EAE relapses. Similarly, <10% of the infectious episodes in the clinical studies were associated with MS exacerbations (8, 9, 10, 11). One explanation is that immunoregulatory mechanisms prevent clinically overt autoimmunity. Alternatively, the number of autoreactive Th cells, which are bystander activated, may be too small to cause damage, and finally some infectious agents may lack the potential to induce bystander activation. That only about one-quarter of MS exacerbations are associated with clinically apparent infections (8, 9, 10, 11) may be due to the fact that some infections are clinically inapparent. Alternatively, additional mechanisms, which are not triggered by infections, could cause exacerbations. The latter possibility is supported by pathological evidence suggesting that there are four distinguishable subgroups of MS (67), each of which may have different immunopathological mechanisms and different susceptibility for infection-induced immunopathology. Even so, aggressive therapy and prophylaxis of infections to prevent bystander activation of autoreactive T cells could be a useful approach in comprehensive treatment of MS patients.

Exacerbations of MS are associated with many different infections, including Gram-positive bacteria and viruses that do not possess LPS (8, 9, 10, 11). We found that bacterial lipoproteins, which are expressed by Gram-positive bacteria, can induce EAE relapses in SJL mice with similar incidence and severity as LPS (V.S. and T.K., unpublished data), and it remains to be established whether other pathogen-associated molecular patterns such as dsRNA are able to induce bystander activation of autoreactive Th cells.

In summary, LPS induces the proliferation and cytokine production of Th cells independently of TCR signaling. This bystander activation of Th cells is not mediated by soluble factors and requires the physical contact between LPS-responsive CD4– cells and Th cells. LPS immunization induces exacerbations of EAE in genetically unaltered normal mice. Bystander activation of autoreactive Th cells is an Ag-independent mechanism that fits the clinical and epidemiological data on the connection between infection and autoimmunity better than Ag-specific models.


   Acknowledgments
 
We thank Ulrich Schaible for lysed S. typhimurium, Andreas Hutloff, Richard Kroczek, and Clemens Sorg for mAbs, Juan Lafaille and Jocelyne Demengeot for mice, Joachim Listing for statistical analyses, and N. Avrion Mitchison for critical reading of this manuscript.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by the Deutsche Forschungsgemeinschaft (SFB 421, TP C2; to T.K.), the Gemeinnützige Hertiestiftung (Molekulare Mimikry und Multiple Sklerose (to T.K.) and Genotype-Phenotype Correlation in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis (to C.S.), the Medical Faculty of the University of Göttingen (Junior Research Group; to C.S.), the Charité Forschungskommission (to A.N. and T.K.), and the Studienstiftung des Deutschen Volkes (to V.S.). Back

2 A.N., V.S., and K.B. contributed equally. Back

3 Address correspondence and reprint requests to Dr. Thomas Kamradt, Institut für Immunologie, Klinikum der FSU Jena, 07743 Jena, Germany. E-mail address: Immunologie{at}mti.uni-jena.de Back

4 Abbreviations used in this paper: MS, multiple sclerosis; CsA, cyclosporin A; EAE, experimental autoimmune encephalomyelitis; ICOS, inducible costimulator; MBP, myelin basic protein; PT, pertussis toxin; SC, spleen cell; SEB, staphylococcal enterotoxin B; CM, complete medium. Back

Received for publication March 11, 2004. Accepted for publication May 13, 2005.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Steinman, L., R. Martin, C. Bernard, P. Conlon, J. R. Oksenberg. 2002. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu. Rev. Neurosci. 25: 491-505.[Medline]
  2. Hemmer, B., J. J. Archelos, H. P. Hartung. 2002. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. 3: 291-301.[Medline]
  3. Compston, A., A. Coles. 2002. Multiple sclerosis. Lancet 359: 1221-1231.[Medline]
  4. Zamvil, S. S., L. Steinman. 1990. The T lymphocyte in experimental allergic encephalitis. Annu. Rev. Immunol. 8: 579-621.[Medline]
  5. Madsen, L. S., E. C. Andersson, L. Jansson, M. Krogsgaard, C. B. Andersen, J. Engberg, J. L. Strominger, A. Svejgaard, J. P. Hjorth, R. Holmdahl, et al 1999. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat. Genet. 23: 343-347.[Medline]
  6. Kuchroo, V. K., A. C. Anderson, H. Waldner, M. Munder, E. Bettelli, L. B. Nicholson. 2002. T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu. Rev. Immunol. 20: 101-123.[Medline]
  7. Kamradt, T., R. Göggel, K. Erb. 2005. Induction, exacerbation and inhibition of allergic and autoimmune diseases by infection. Trends Immunol. 26: 260-267.[Medline]
  8. Sibley, W. A., C. R. Bamford, K. Clark. 1985. Clinical viral infections and multiple sclerosis. Lancet 1: 1313-1315.[Medline]
  9. Andersen, O., P. E. Lygner, T. Bergstrom, M. Andersson, A. Vahlne. 1993. Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J. Neurol. 240: 417-422.[Medline]
  10. Panitch, H. S.. 1994. Influence of infection on exacerbations of multiple sclerosis. Ann. Neurol. 36: S25-S28.
  11. Buljevac, D., H. Z. Flach, W. C. Hop, D. Hijdra, J. D. Laman, H. F. Savelkoul, F. G. van Der Meche, P. A. van Doorn, R. Q. Hintzen. 2002. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125: 952-960.[Abstract/Free Full Text]
  12. Fujinami, R. S., M. B. A. Oldstone, Z. Wroblewska, M. E. Frankel, H. Koprowski. 1983. Molecular mimicry in virus infection: crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. Proc. Natl. Acad. Sci. USA 80: 2346-2350.[Abstract/Free Full Text]
  13. Benoist, C., D. Mathis. 2001. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry?. Nat. Immunol. 2: 797-801.[Medline]
  14. Wucherpfennig, K. W., J. L. Strominger. 1995. Molecular mimicry in T-cell mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80: 695-705.[Medline]
  15. Hemmer, B., B. T. Fleckenstein, M. Vergelli, G. Jung, H. McFarland, R. Martin, K.-H. Wiesmüller. 1997. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone. J. Exp. Med. 185: 1651-1659.[Abstract/Free Full Text]
  16. Gautam, A. M., R. Liblau, G. Chelvanayagam, L. Steinman, T. Boston. 1998. A viral peptide with limited homology to a self peptide can induce clinical signs of experimental autoimmune encephalomyelitis. J. Immunol. 161: 60-64.[Abstract/Free Full Text]
  17. Grogan, J. L., A. Kramer, A. Nogai, L. Dong, M. Ohde, J. Schneider-Mergener, T. Kamradt. 1999. Cross-reactivity of myelin basic protein-specific T cells with multiple microbial peptides: experimental autoimmune encephalomyelitis induction in TCR transgenic mice. J. Immunol. 163: 3764-3770.[Abstract/Free Full Text]
  18. Ufret-Vincenty, R. L., L. Quigley, N. Tresser, S. H. Pak, A. Gado, S. Hausmann, K. W. Wucherpfennig, S. Brocke. 1998. In vivo survival of viral antigen-specific T cells that induce experimental autoimmune encephalomyelitis. J. Exp. Med. 188: 1725-1728.[Abstract/Free Full Text]
  19. Kurtzke, J. F.. 1993. Epidemiologic evidence for multiple sclerosis as an infection. Clin. Microbiol. Rev. 6: 382-427.[Abstract/Free Full Text]
  20. Atkins, G. J., S. McQuaid, M. M. Morris-Downes, S. E. Galbraith, S. Amor, S. L. Cosby, B. J. Sheahan. 2000. Transient virus infection and multiple sclerosis. Rev. Med. Virol. 10: 291-303.[Medline]
  21. Kamradt, T., R. Volkmer-Engert. 2004. Cross-reactivity of T lymphocytes in infection and autoimmunity. Mol. Divers 8: 271-280.[Medline]
  22. Kamradt, T., N. A. Mitchison. 2001. Tolerance and autoimmunity. N. Engl. J. Med. 344: 655-664.[Free Full Text]
  23. Carreno, B. M., M. Collins. 2002. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20: 29-53.[Medline]
  24. Croft, M.. 2003. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?. Nat. Rev. Immunol. 3: 609-620.[Medline]
  25. Janeway, C. A., Jr, R. Medzhitov. 2002. Innate immune recognition. Annu. Rev. Immunol. 20: 197-216.[Medline]
  26. Takeda, K., T. Kaisho, S. Akira. 2003. Toll-like receptors. Annu. Rev. Immunol. 21: 335-376.[Medline]
  27. Lafaille, J. J., K. Nagashima, M. Katsuki, S. Tonegawa. 1994. High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice. Cell 78: 399-408.[Medline]
  28. Vass, K., H. Lassmann, H. Wekerle, H. M. Wisniewski. 1986. The distribution of Ia antigen in the lesions of rat acute experimental allergic encephalomyelitis. Acta Neuropathol. 70: 149-160.[Medline]
  29. Nacken, W., C. Sopalla, C. Propper, C. Sorg, C. Kerkhoff. 2000. Biochemical characterization of the murine S100A9 (MRP14) protein suggests that it is functionally equivalent to its human counterpart despite its low degree of sequence homology. Eur. J. Biochem. 267: 560-565.[Medline]
  30. Bonhagen, K., O. Liesenfeld, M. Stadecker, A. Hutloff, K. Erb, A. J. Coyle, M. Lipp, R. Kroczek, T. Kamradt. 2003. ICOS+ Th cells produce distinct cytokines in different mucosal immune responses. Eur. J. Immunol. 33: 392-401.[Medline]
  31. Brabb, T., A. W. Goldrath, P. von Dassow, A. Paez, H. D. Liggitt, J. Goverman. 1997. Triggers of autoimmune disease in a murine TCR-transgenic model for multiple sclerosis. J. Immunol. 159: 497-507.[Abstract]
  32. Yang, J., H. Zhu, T. L. Murphy, W. Ouyang, K. M. Murphy. 2001. IL-18-stimulated GADD45{beta} required in cytokine-induced, but not TCR- induced, IFN-{gamma} production. Nat. Immunol. 2: 157-164.[Medline]
  33. Hamada, T., B. F. Driscoll, M. W. Kies, E. C. Alvord, Jr. 1989. LPS augments adoptive transfer of experimental allergic encephalomyelitis in the Lewis rat. Autoimmunity 2: 275-284.[Medline]
  34. Segal, B. M., D. M. Klinman, E. M. Shevach. 1997. Microbial products induce autoimmune disease by an IL-12-dependent pathway. J. Immunol. 158: 5087-5090.[Abstract]
  35. Kissler, S., S. M. Anderton, D. C. Wraith. 2001. Antigen-presenting cell activation: a link between infection and autoimmunity?. J. Autoimmun. 16: 303-308.[Medline]
  36. Ichikawa, H. T., L. P. Williams, B. M. Segal. 2002. Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. J. Immunol. 169: 2781-2787.[Abstract/Free Full Text]
  37. Conant, S. B., R. H. Swanborg. 2004. Autoreactive T cells persist in rats protected against experimental autoimmune encephalomyelitis and can be activated through stimulation of innate immunity. J. Immunol. 172: 5322-5328.[Abstract/Free Full Text]
  38. Waldner, H. P., M. Collins, V. K. Kuchroo. 2004. Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J. Clin. Invest. 113: 990-997.[Medline]
  39. Kamradt, T., P. D. Soloway, D. L. Perkins, M. L. Gefter. 1991. Pertussis toxin prevents the induction of peripheral T cell anergy and enhances the T cell response to an encephalitogenic peptide of myelin basic protein. J. Immunol. 147: 3296-3302.[Abstract]
  40. Hofstetter, H. H., C. L. Shive, T. G. Forsthuber. 2002. Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund’s adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells. J. Immunol. 169: 117-125.[Abstract/Free Full Text]
  41. Kerfoot, S. M., E. M. Long, M. J. Hickey, G. Andonegui, B. M. Lapointe, R. C. O. Zanardo, C. Bonder, W. G. James, S. M. Robbins, P. Kubes. 2004. TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J. Immunol. 173: 7070-7077.[Abstract/Free Full Text]
  42. Unutmaz, D., P. Pileri, S. Abrignani. 1994. Antigen-independent activation of naive and memory resting T cells by a cytokine combination. J. Exp. Med. 180: 1159-1164.[Abstract/Free Full Text]
  43. Geginat, J., F. Sallusto, A. Lanzavecchia. 2001. Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4+ T cells. J. Exp. Med. 194: 1711-1719.[Abstract/Free Full Text]
  44. Yang, J., T. L. Murphy, W. Ouyang, K. M. Murphy. 1999. Induction of interferon-{gamma} production in Th1 CD4+ T cells: evidence for two distinct pathways for promoter activation. Eur. J. Immunol. 29: 548-555.[Medline]
  45. Tough, D. F., P. Borrow, J. Sprent. 1996. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272: 1947-1950.[Abstract]
  46. Tough, D. F., S. Sun, J. Sprent. 1997. T cell stimulation in vivo by lipopolysaccharide (LPS). J. Exp. Med. 185: 2089-2094.[Abstract/Free Full Text]
  47. Zhang, X., S. Sun, I. Hwang, D. F. Tough, J. Sprent. 1998. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 8: 591-599.[Medline]
  48. Pasare, C., R. Medzhitov. 2003. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299: 1033-1036.[Abstract/Free Full Text]
  49. Brennan, F. M., A. L. Hayes, C. J. Ciesielski, P. Green, B. M. Foxwell, M. Feldmann. 2002. Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor {kappa}B pathways in tumor necrosis factor {alpha} production in rheumatoid arthritis. Arthritis Rheum. 46: 31-41.[Medline]
  50. Caramalho, I., T. Lopes-Carvalho, D. Ostler, S. Zelenay, M. Haury, J. Demengeot. 2003. Regulatory T cells selectively express Toll-like receptors and are activated by lipopolysaccharide. J. Exp. Med. 197: 403-411.[Abstract/Free Full Text]
  51. Perez, O. D., D. Mitchell, G. C. Jager, S. South, C. Murriel, J. McBride, L. A. Herzenberg, S. Kinoshita, G. P. Nolan. 2003. Leukocyte functional antigen 1 lowers T cell activation thresholds and signaling through cytohesin-1 and Jun-activating binding protein 1. Nat. Immunol. 4: 1083-1092.[Medline]
  52. Tacke, M., G. Hanke, T. Hanke, T. Hunig. 1997. CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur. J. Immunol. 27: 239-247.[Medline]
  53. Luhder, F., Y. Huang, K. M. Dennehy, C. Guntermann, I. Muller, E. Winkler, T. Kerkau, S. Ikemizu, S. J. Davis, T. Hanke, T. Hunig. 2003. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J. Exp. Med. 197: 955-966.[Abstract/Free Full Text]
  54. Meuer, S. C., R. E. Hussey, M. Fabbi, D. Fox, O. Acuto, K. A. Fitzgerald, J. C. Hodgdon, J. P. Protentis, S. F. Schlossman, E. L. Reinherz. 1984. An alternative pathway of T-cell activation: a functional role for the 50 kd T11 sheep erythrocyte receptor protein. Cell 36: 897-906.[Medline]
  55. Bernasconi, N. L., E. Traggiai, A. Lanzavecchia. 2002. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298: 2199-2202.[Abstract/Free Full Text]
  56. Pette, M., K. Fujita, B. Kitze, J. N. Whitaker, E. Albert, L. Kappos, H. Wekerle. 1990. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 40: 1770-1776.[Abstract/Free Full Text]
  57. Ota, K., M. Matsui, E. L. Milford, G. A. Mackin, H. L. Weiner, D. A. Hafler. 1990. T cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 346: 183-187.[Medline]
  58. Martin, R., D. Jaraquemada, M. Flerlage, J. Richert, J. Whitaker, E. O. Long, D. E. McFarlin, H. F. McFarland. 1990. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J. Immunol. 145: 540-548.[Abstract]
  59. Anderson, A. C., L. B. Nicholson, K. L. Legge, V. Turchin, H. Zaghouani, V. K. Kuchroo. 2000. High frequency of autoreactive myelin proteolipid protein-specific T cells in the periphery of naive mice: mechanisms of selection of the self-reactive repertoire. J. Exp. Med. 191: 761-770.[Abstract/Free Full Text]
  60. Skidmore, B. J., J. M. Chiller, W. O. Weigle, R. Riblet, J. Watson. 1976. Immunologic properties of bacterial lipopolysaccharide (LPS). III. Genetic linkage between the in vitro mitogenic and in vivo adjuvant properties of LPS. J. Exp. Med. 143: 143-150.[Abstract/Free Full Text]
  61. Segal, B. M., B. K. Dwyer, E. M. Shevach. 1998. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J. Exp. Med. 187: 537-546.[Abstract/Free Full Text]
  62. Reis e Sousa, C., R. N. Germain. 1999. Analysis of adjuvant function by direct visualization of antigen presentation in vivo: endotoxin promotes accumulation of antigen- bearing dendritic cells in the T cell areas of lymphoid tissue. J. Immunol. 162: 6552-6561.[Abstract/Free Full Text]
  63. Mitchell, T. C., D. Hildeman, R. M. Kedl, T. K. Teague, B. C. Schaefer, J. White, Y. Zhu, J. Kappler, P. Marrack. 2001. Immunological adjuvants promote activated T cell survival via induction of Bcl-3. Nat. Immunol. 2: 397-402.[Medline]
  64. Horwitz, M. S., L. M. Bradley, J. Harbertson, T. Krahl, J. Lee, N. Sarvetnick. 1998. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat. Med. 4: 781-785.[Medline]
  65. Panoutsakopoulou, V., M. E. Sanchirico, K. M. Huster, M. Jansson, F. Granucci, D. J. Shim, K. W. Wucherpfennig, H. Cantor. 2001. Analysis of the relationship between viral infection and autoimmune disease. Immunity 15: 137-147.[Medline]
  66. Haring, J. S., L. L. Pewe, S. Perlman. 2002. Bystander CD8 T cell-mediated demyelination after viral infection of the central nervous system. J. Immunol. 169: 1550-1555.[Abstract/Free Full Text]
  67. Lucchinetti, C., W. Brück, J. Parisi, B. Scheithauer, M. Rodriguez, H. Lassmann. 2000. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47: 707-717.[Medline]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
K. K. Ellestad, S. Tsutsui, F. Noorbakhsh, K. G. Warren, V. W. Yong, Q. J. Pittman, and C. Power
Early Life Exposure to Lipopolysaccharide Suppresses Experimental Autoimmune Encephalomyelitis by Promoting Tolerogenic Dendritic Cells and Regulatory T Cells
J. Immunol., July 1, 2009; 183(1): 298 - 309.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. C. Bangs, D. Baban, H. J. Cattan, C. K.-F. Li, A. J. McMichael, and X.-N. Xu
Human CD4+ Memory T Cells Are Preferential Targets for Bystander Activation and Apoptosis
J. Immunol., February 15, 2009; 182(4): 1962 - 1971.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
A. Martin-Fontecha, D. Baumjohann, G. Guarda, A. Reboldi, M. Hons, A. Lanzavecchia, and F. Sallusto
CD40L+ CD4+ memory T cells migrate in a CD62P-dependent fashion into reactive lymph nodes and license dendritic cells for T cell priming
J. Exp. Med., October 27, 2008; 205(11): 2561 - 2574.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
A. Krupa, M. J. Walencka, V. Shrivastava, T. Loyd, R. Fudala, C. W. Frevert, T. R. Martin, and A. K. Kurdowska
Anti-KC Autoantibody:KC Complexes Cause Severe Lung Inflammation in Mice via IgG Receptors
Am. J. Respir. Cell Mol. Biol., November 1, 2007; 37(5): 532 - 543.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
I. Herrmann, M. Kellert, A. Spreer, J. Gerber, H. Eiffert, M. Prinz, and R. Nau
Minocycline delays but does not attenuate the course of experimental autoimmune encephalomyelitis in Streptococcus pneumoniae-infected mice
J. Antimicrob. Chemother., January 1, 2007; 59(1): 74 - 79.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
I. Herrmann, M. Kellert, H. Schmidt, A. Mildner, U. K. Hanisch, W. Bruck, M. Prinz, and R. Nau
Streptococcus pneumoniae Infection Aggravates Experimental Autoimmune Encephalomyelitis via Toll-Like Receptor 2.
Infect. Immun., August 1, 2006; 74(8): 4841 - 4848.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nogai, A.
Right arrow Articles by Kamradt, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nogai, A.
Right arrow Articles by Kamradt, T.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CYCLOSPORIN A

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS